[CLSTR]
< Back to situations

We’ll email you as it develops, and you can follow the whole thread from day one.

[SITUATION] · [ACTIVE]

2 clusters · 2 sources · 20 days · First seen · Last updated

Categories: HEALTH

Global rollout of once‑weekly insulin

Entities: Awiqli (insulin icodec‑abae) · American Diabetes Association · Regular insulin · Food and Drug Administration · Shichun Bao

Overview

Novo Nordisk’s insulin icodec‑abae, marketed as Awiqli, received US FDA approval in March 2026 as the first once‑weekly formulation for adults with type 2 diabetes. By early July the product was launched in India, extending its availability beyond the United States.

The same period saw broader discussion of insulin affordability, with over‑the‑counter regular insulin being promoted in the US as a lower‑cost alternative, while Awiqli’s weekly dosing was highlighted as a convenient option for patients struggling with daily injection regimens.

Together, these developments illustrate a coordinated push to expand access to newer insulin therapies worldwide while also addressing cost barriers through OTC options.

Timeline

  1. about 11 hours ago

    [HEALTH] 2 sources
    Insulin Options Expand: OTC Regular and Once‑Weekly Formulations

    Over‑the‑counter regular insulin offers a low‑cost, older option amid U.S. affordability challenges, while the newly FDA‑approved once‑weekly insulin (Awiqli) provides convenient dosing for Type 2 diabetes.

  2. 20 days ago

    [HEALTH] 8 sources
    India launches Novo Nordisk’s once‑weekly insulin Awiqli

    Novo Nordisk launched Awiqli, the world’s first once‑weekly basal insulin, in India, cutting yearly injections from 365 to 52 and aiming to ease treatment for over 100 million diabetics.

Sources

diabetesdaily.com · krdo.com